Monographs / SGLT2 Inhibitors – No Longer Just for Those with Diabetes
expert
Cardiologist; Appoints at Medical School, Deakin University
SGLT2 inhibitors are rapidly becoming seen as cardiac drugs in their own right, above and beyond their role in diabetes.
Written by A/Prof John Amerena MBBS, PhD, FRACP, FCSANZ
A/Prof John Amerena trained in Melbourne before spending four years in the United States at the University of Michigan. He is now a Cardiologist at Barwon Health, and currently has appointments in the Medical School, Deakin University and the Department of Epidemiology and Preventive Medicine at Monash University. He is the Director of the Geelong Cardiology Research Unit which is currently involved in many phase II-III clinical trials, as well as Director of Cardiac Services at Geelong Private Hospital. While still involved in hypertension,he has also become involved in research in atherothrombosis.
Functional Gastrointestinal Disorders in Infants – Practical Advice for HCPs
TIAs and Carotid Stenosis
Low libido - What is it & How is it Managed?
Using the New RSV Vaccine in Practice
expert
Cardiologist; Appoints at Medical School, Deakin University
Strongly support
Somewhat support
Neither support nor oppose
Somewhat oppose
Strongly oppose
Listen to expert interviews.
Click to open in a new tab
Browse the latest monographs from Healthed.
You have completed the Educational Activities component of this resource.
Select ‘Confirm & claim CPD‘ to confirm you have engaged with this resource in its entirety and claim your CPD.
You will be taken to explore further CPD learning available to you.